Dermatology · Research Phase
Haloxyl (Chrysin + Palmitoyl Peptides)
No lawful US pathway
01 · Overview
Haloxyl is a proprietary cosmetic ingredient combining chrysin, a naturally occurring flavone, with palmitoyl peptides, marketed to reduce under-eye dark circles and puffiness. The rationale for chrysin is that it can induce UGT1A1, the enzyme that conjugates bilirubin for clearance; in human liver cancer cells, chrysin increased bilirubin glucuronidation about 20-fold (PMID 10950852), although this has not been shown in skin.
The supplier claims the palmitoyl peptides firm the skin and improve drainage, but these effects have not been confirmed in independent peer-reviewed studies.
02 · Research summary & key findings
No peer-reviewed studies of Haloxyl itself were found in PubMed. Chrysin is one of many natural actives reviewed for periorbital hyperpigmentation (PMID 32472659), and an open-label 12-week study of a multi-ingredient eye cream containing chrysin, caffeine, and botanical extracts reported improvements in dark circles and puffiness in 37 women (PMID 38112168); this product was not shown to be Haloxyl, and the effect of individual ingredients cannot be separated. Manufacturer-reported chromametry results have not been independently replicated, and long-term safety data are not published.
03 · Regulatory status
Haloxyl (Chrysin + Palmitoyl Peptides) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
No lawful pathway today
Haloxyl (Chrysin + Palmitoyl Peptides) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 1 FDA-approved compound in Dermatology
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for longevity and healthy ageing?
Haloxyl (Chrysin + Palmitoyl Peptides) is a research compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on longevity and healthy ageing, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Topical
References
- [1]Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line hep G2 Drug Metab Dispos, 2000. PMID 10950852
- [2]Management of periorbital hyperpigmentation: An overview of nature-based agents and alternative approaches Dermatol Ther, 2020. PMID 32472659
- [3]Effectiveness and tolerance of multicorrective topical treatment for infraorbital dark circles and puffiness J Cosmet Dermatol, 2024. PMID 38112168
Primary literature
- PubMed: "Haloxyl"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Haloxyl"
Registered interventional and observational studies, including status and phase.
- PubChem: "Haloxyl"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Dermatology
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.